Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 87 of the 90 references it cites were found in a registry or an index.

Dual Hyaluronic Acid and Folic Acid Targeting pH-Sensitive Multifunctional 2DG@DCA@MgO-Nano-Core-Shell-Radiosensitizer for Breast Cancer Therapy

Open access

Preprint — published as 10.3390/cancers13215571

Abstract

Background: Globally, breast cancer (BC) poses a serious public health risk. The disease exhibits a complex heterogeneous etiology and is associated with glycolysis and oxidative phosphorylation (OXPHOS) metabolic reprograming pathways which fuel proliferation and progression. Due to the late manifestation of symptoms, rigorous treatment regimens are required following diagnosis. Existing treatments are limited by a lack of specificity, systemic toxicity, temporary remission, and radio-resistance in BC. In this study, we developed CD44 and folate receptor-targeting multi-functional dual drug-loaded nanoparticles (DDM). These contained a hyaluronic acid (HA) and folic acid (FA) conjugated to a dichloroacetate (DCA) shell linked to a 2-deoxy glucose (2DG) and magnesium oxide (MgO) core to enhance localized chemo-radiotherapy for effective BC treatment.Methods: The physicochemical properties of nanoparticles, including stability, selectivity, release in response to pH, cellular uptake, and anticancer efficacy were comprehensively examined. Mechanistically, we identified multiple component signal pathways as important regulators of BC metabolism and mediators of inhibitory effects toward DDM.Results: Nanoparticles exhibited sustained DDM release properties in bio-relevant media, which was responsive to acidic pH providing flexibility to the control of drug release from nanoparticles. DDM-loaded and HA-FA-functionalized nanoparticles exhibited increased selectivity and uptake by BC cells. Cells study indicated that functionalized DDM significantly suppressed cancer cell growth and radiotherapy (RT) improvement via cell cycle arrest, apoptosis enhancement, and modulation of glycolysis and OXPHOS pathways.Conclusions: By highlighting DDM mechanisms as an antitumor and radio-sensitizing reagent, our analysis also revealed glycolysis and OXPHOS modulation via PI3K/AKT/mTOR/NF-κB/VEGF low and P53 high signal pathways. In conclusion, we indicated that multi-functionalized DDM depletion-mediated metabolic reprogramming via multiple signal pathways in BC cells is a promising targeted metabolic therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21203/rs.3.rs-910507/v1

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Characteristics of DDM. (a) Diagram of DDM synthesis. (b) The crystallinity behavior of MgO-NPs, and amorphous shape of organic shells in the synthesized DDM by XRD analysis. (c) EDX spectra of the synthesized DDM. (d) Elemental mapping images of the synthesized DDM.
Figure 1 Characteristics of DDM. (a) Diagram of DDM synthesis. (b) The crystallinity behavior of MgO-NPs, and amorphous shape of organic shells in the synthesized DDM by XRD analysis. (c) EDX spectra of the synthesized DDM. (d) Elemental mapping images of the synthesized DDM.CC BY · PubMed Central
Figure 2 Structural characteristics of DDM. (a) SEM images of the synthesized core-shell DDM sample at different magnifications. (b) HRTEM images of the synthesized core-shell DDM at different magnifications. (c) FTIR analysis of the synthesized core-shell DDM. (d) Stability of DDM in PBS containing 10% FBS indicated by DLS and zeta potential analyses.
Figure 2 Structural characteristics of DDM. (a) SEM images of the synthesized core-shell DDM sample at different magnifications. (b) HRTEM images of the synthesized core-shell DDM at different magnifications. (c) FTIR analysis of the synthesized core-shell DDM. (d) Stability of DDM in PBS containing 10% FBS indicated by DLS and zeta potential analyses.CC BY · PubMed Central
Figure 3 Inhibition of breast cancer (BC) cell proliferation, release, enhanced selectivity, and cellular uptake by DDM. (a) MTT assay of BC cells treated with DDM at different concentrations. Values are represented as the mean ± standard error of the mean (SEM) of triplicate samples from two independent experiments. (b) Phase-contrast images of MCF-7 and MDA-MB-231 cells were captured by the inverted light microscope. (c) The release of DDM at different pH; originally 3, 7, and 9 phosphate buffer solutions (PBS) containing DMSO 0.1% estimated using UV-vis spectrometry. (d) Representative histogram of the selective HA, CD44, and FR-α expression in BC cells. (e) Flow-cytometric images showing a single parameter histogram for CD44 in different groups, where the M1 denotes the cell population stained with the CD44 antibody. (f) Atomic absorption spectrophotometry (AAS) intracellular MgO uptake data in MCF-10A, MCF-7, and MDA-MB-231 cells after 24 h incubation with DDM at IC50 doses. (g) Transmission electron microscopy (TEM) images of MCF-10A, MCF-7, and MDA-MB-231 DDM uptake after 24 h incubation with DDM at IC50 doses. Data are represented as the mean ± standard error of the mean (SEM) (n = 3). a1 p < 0.001, a2 p < 0.01 vs. untreated normal cells; b1 p < 0.001, b2 p < 0.01 vs. untreated cancer cells.
Figure 3 Inhibition of breast cancer (BC) cell proliferation, release, enhanced selectivity, and cellular uptake by DDM. (a) MTT assay of BC cells treated with DDM at different concentrations. Values are represented as the mean ± standard error of the mean (SEM) of triplicate samples from two independent experiments. (b) Phase-contrast images of MCF-7 and MDA-MB-231 cells were captured by the inverted light microscope. (c) The release of DDM at different pH; originally 3, 7, and 9 phosphate buffer solutions (PBS) containing DMSO 0.1% estimated using UV-vis spectrometry. (d) Representative histogram of the selective HA, CD44, and FR-α expression in BC cells. (e) Flow-cytometric images showing a single parameter histogram for CD44 in different groups, where the M1 denotes the cell population stained with the CD44 antibody. (f) Atomic absorption spectrophotometry (AAS) intracellular MgO uptake data in MCF-10A, MCF-7, and MDA-MB-231 cells after 24 h incubation with DDM at IC50 doses. (g) Transmission electron microscopy (TEM) images of MCF-10A, MCF-7, and MDA-MB-231 DDM uptake after 24 h incubation with DDM at IC50 doses. Data are represented as the mean ± standard error of the mean (SEM) (n = 3). a1 p < 0.001, a2 p < 0.01 vs. untreated normal cells; b1 p < 0.001, b2 p < 0.01 vs. untreated cancer cells.CC BY · PubMed Central
Figure 4 Cell survival and radio-sensitization rates using the multi-MTT assay. (a) Experimental schematic outline of the six different treatment groups. Evaluation of cell survival (b,c), percent inhibition for MCF-7 (d), percent inhibition for MDA-MB-231 (e), and dose-modifying effect curves (f,g) in response to DDM, 3Gy-SDR, or 6Gy-FDR, and a combination of both at 24 h, 48 h and 72 h using the multi-MTT assay. Data are the mean ± standard error of the mean (SEM), where control cells are 100% (n = 3). a p < 0.01 vs. control; b p < 0.01 vs. DDM group; c p < 0.001 vs. 3Gy-SDR or 6Gy-FDR groups; d p < 0.05 vs. 3Gy-SDR+DDM group.
Figure 4 Cell survival and radio-sensitization rates using the multi-MTT assay. (a) Experimental schematic outline of the six different treatment groups. Evaluation of cell survival (b,c), percent inhibition for MCF-7 (d), percent inhibition for MDA-MB-231 (e), and dose-modifying effect curves (f,g) in response to DDM, 3Gy-SDR, or 6Gy-FDR, and a combination of both at 24 h, 48 h and 72 h using the multi-MTT assay. Data are the mean ± standard error of the mean (SEM), where control cells are 100% (n = 3). a p < 0.01 vs. control; b p < 0.01 vs. DDM group; c p < 0.001 vs. 3Gy-SDR or 6Gy-FDR groups; d p < 0.05 vs. 3Gy-SDR+DDM group.CC BY · PubMed Central
Figure 5 DDM and/or RT induced cell cycle arrest and apoptosis in BC cells. (a–c) Representative cell cycle images of MCF7 and MDA-MB-321 cells at G2/M arrest after a 24 h treatment with DDM or DDM + RT, and cycle arrest at S phase in MCF-7 and G1 phase in MDA-MB-231 when treated with RT only. (d–f) A representative dot plot of annexin-V-FITC and PI staining in BC cells treated with DDM or DDM + RT for 24 h showing increased apoptotic cells when compared with controls or RT alone. Slightly increased apoptotic cells are seen in the RT group compared to the control. Data are the mean ± standard error of the mean (SEM). a1 p < 0.001, a2 p < 0.01, a3 p < 0.05 vs. control; b1 p < 0.001, b2 p < 0.01, b3 p < 0.05 vs. DDM group; c1 p < 0.001, c2 p < 0.01, c3 p < 0.05 vs. RT group.
Figure 5 DDM and/or RT induced cell cycle arrest and apoptosis in BC cells. (a–c) Representative cell cycle images of MCF7 and MDA-MB-321 cells at G2/M arrest after a 24 h treatment with DDM or DDM + RT, and cycle arrest at S phase in MCF-7 and G1 phase in MDA-MB-231 when treated with RT only. (d–f) A representative dot plot of annexin-V-FITC and PI staining in BC cells treated with DDM or DDM + RT for 24 h showing increased apoptotic cells when compared with controls or RT alone. Slightly increased apoptotic cells are seen in the RT group compared to the control. Data are the mean ± standard error of the mean (SEM). a1 p < 0.001, a2 p < 0.01, a3 p < 0.05 vs. control; b1 p < 0.001, b2 p < 0.01, b3 p < 0.05 vs. DDM group; c1 p < 0.001, c2 p < 0.01, c3 p < 0.05 vs. RT group.CC BY · PubMed Central
Figure 6 The influence of DDM and/or RT on glycolysis and mitochondrial metabolic pathways in BC cells. (a,b) Glucose, hexokinase, and lactate levels were analyzed by colorimetric assay in all groups. (c) mRNA and protein expression of PKM2 was rescued in all groups. (d,e) HIF-1α, PDK1, SIRT1, and SIRT3 protein expression and PDH enzymatic activity was rescued in all groups. (f) Relative SIRT1, SIRT3, and β-actin protein levels in all groups. (g) ROS levels (ELISA) in all groups. All group values are given as the mean ± standard error of the mean (SEM). a1 p < 0.001, a2 p < 0.01, a3 p < 0.05 vs. control; b1 p < 0.001, b2 p < 0.01, b3 p < 0.05 vs. DDM group; c1 p < 0.001, c2 p < 0.01, c3 p < 0.05 vs. RT group.
Figure 6 The influence of DDM and/or RT on glycolysis and mitochondrial metabolic pathways in BC cells. (a,b) Glucose, hexokinase, and lactate levels were analyzed by colorimetric assay in all groups. (c) mRNA and protein expression of PKM2 was rescued in all groups. (d,e) HIF-1α, PDK1, SIRT1, and SIRT3 protein expression and PDH enzymatic activity was rescued in all groups. (f) Relative SIRT1, SIRT3, and β-actin protein levels in all groups. (g) ROS levels (ELISA) in all groups. All group values are given as the mean ± standard error of the mean (SEM). a1 p < 0.001, a2 p < 0.01, a3 p < 0.05 vs. control; b1 p < 0.001, b2 p < 0.01, b3 p < 0.05 vs. DDM group; c1 p < 0.001, c2 p < 0.01, c3 p < 0.05 vs. RT group.CC BY · PubMed Central
Figure 7 DDM and/or RT modulate key proteins involved in the regulation of glycolysis and OXPHOS pathways in BC cells. PI3K, AKT, mTOR, P53, and β-actin protein levels in MCF-7 cells (a,b) and MDA-MB-231 cells (d,e). NF-κB and VEGF levels (ELISA) in both cell groups (c,f). (g) Schematic representing the mode of action of targeted multifunctional core–shell-nano (DDM) and RT. The DDM core–shell is a chemotherapy drug targeted to cancer cell surfaces via cancer cell-specific ligands. DDM binds to surfaces by recognizing specific receptors resulting in DDM internalization via endocytosis. Inside the cell, DDM undergoes endosomal escape leading to cytotoxic drug release. Treatment with DDM alone or as a radio-sensitizer (prior to RT) induces cancer cell death through modulating the metabolic reprogramming displayed by BC cells via a novel PI3K/AKT/mTOR/P53/NF-κB/VEGF pathway. (→) Indicates pathway direction and (T) indicates blocking functions. All group values are presented as the mean ± standard error of the mean (SEM). a1 p < 0.001, a2 p < 0.01, a3 p < 0.05 vs. control; b2 p < 0.01, b3 p < 0.05 vs. DDM group; c1 p < 0.001, c2 p < 0.01, c3 p < 0.05 vs. RT group.
Figure 7 DDM and/or RT modulate key proteins involved in the regulation of glycolysis and OXPHOS pathways in BC cells. PI3K, AKT, mTOR, P53, and β-actin protein levels in MCF-7 cells (a,b) and MDA-MB-231 cells (d,e). NF-κB and VEGF levels (ELISA) in both cell groups (c,f). (g) Schematic representing the mode of action of targeted multifunctional core–shell-nano (DDM) and RT. The DDM core–shell is a chemotherapy drug targeted to cancer cell surfaces via cancer cell-specific ligands. DDM binds to surfaces by recognizing specific receptors resulting in DDM internalization via endocytosis. Inside the cell, DDM undergoes endosomal escape leading to cytotoxic drug release. Treatment with DDM alone or as a radio-sensitizer (prior to RT) induces cancer cell death through modulating the metabolic reprogramming displayed by BC cells via a novel PI3K/AKT/mTOR/P53/NF-κB/VEGF pathway. (→) Indicates pathway direction and (T) indicates blocking functions. All group values are presented as the mean ± standard error of the mean (SEM). a1 p < 0.001, a2 p < 0.01, a3 p < 0.05 vs. control; b2 p < 0.01, b3 p < 0.05 vs. DDM group; c1 p < 0.001, c2 p < 0.01, c3 p < 0.05 vs. RT group.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 90 references

Research works printed but not linked: 3

  1. Tiziana Tataranni and Claudia Piccoli. Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications. Oxidative Medicine Cellular Longevity. 2019;7:1-14. DOI.org/10.1155/2019/8201079. · DOI · Paper page
  2. ISO/ASTM E 51026 Practice for using the fricke dosimeter system. ASTM international, Switzerland. 2015;1:1. https://www.sis.se/std-919097.
  3. Yu W, et al. SIRT6 promotes the Warburg effect of papillary thyroid cancer cell BCPAP through reactive oxygen species. Onco Targets Ther. 2019;12:2861-8. https://doi.org/10.2147/OTT.S194256. · DOI

Cited by

See all 27

Metadata

Authors
Askar, M. A., Thabet, N. M., El-sayyad, G. S., El-Batal, A. I., kodous, M. A. E., Kawamura, G., Matsuda, A., Shawi, O. E. E., Helal, H., & Abdel-Rafei, M. K.
Affiliations
  • Egyptian Atomic Energy Authority (EG)
  • Toyohashi University of Technology: Toyohashi Gijutsu Kagaku Daigaku
  • Toyohashi University of Technology (JP)
  • Egyptian Atomic Energy Authority
  • Al-Azhar University (EG)
Corresponding author
  • Askar, Mostafa A.
  • El-sayyad, Gharieb S.
Venue
Cancers
Published
2021-09-28
Volume
13
Issue
21
Pages
5571-5571
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3214132122
Cited by
27
References
90
Citations by year
2026: 5 · 2025: 7 · 2024: 4 · 2023: 7 · 2022: 4
FWCI
0.98
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Mansoura University
  • Japan Society for the Promotion of Science (18H03841 and 21K18823)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
Keywords
breast cancer, hyaluronic acid, folic acid, 2-deoxyglucose, dichloroacetate, magnesium oxide nanoparticles, core-shell nanoparticles, pH-responsive drug release, CD44 targeting, folate receptor targeting, chemoradiotherapy, radiosensitization, tumor metabolic reprogramming, glycolysis, oxidative phosphorylation, PI3K/AKT/mTOR pathway, NF-κB signaling, VEGF signaling, p53 pathway, apoptosis, cell cycle arrest

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual Hyaluronic Acid and Folic Acid Targeting pH-Sensitive Multifunctional 2DG@DCA@MgO-Nano-Core-Shell-Radiosensitizer for Breast Cancer Therapy. https://app.cochat.ai/papers/10.21203/rs.3.rs-910507/v1
The paper
Askar, M. A., Thabet, N. M., El-sayyad, G. S., El-Batal, A. I., kodous, M. A. E., Kawamura, G., Matsuda, A., Shawi, O. E. E., Helal, H., & Abdel-Rafei, M. K. (2021). Dual Hyaluronic Acid and Folic Acid Targeting pH-Sensitive Multifunctional 2DG@DCA@MgO-Nano-Core-Shell-Radiosensitizer for Breast Cancer Therapy. Cancers. https://doi.org/10.21203/rs.3.rs-910507/v1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.